RxDoctor Payments Data

Lisa Bauer, PA

Physician Assistant · Portland, ORNPI 1356585186

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 41 payments — averaging $63.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$774
  • Boston Scientific$274
  • Impulse Dynamics (USA) Inc.$150
  • Alnylam Pharmaceuticals Inc.$120
  • Johnson & Johnson$67
  • plus $99 from 4 others

What the payments were for

  • Food & beverage$2,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott14$1,126
Edwards Lifesciences13$774
Boston Scientific4$274
Impulse Dynamics (USA) Inc.1$150
Alnylam Pharmaceuticals Inc.1$120
Johnson & Johnson3$67
Cardiac Dimensions, Inc.1$31
Pfizer2$25
Novartis1$23
Amgen1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,610 in reported general payments places this provider in the 90th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$70,675
Medicare patients
283
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$97,603
EntrestoSacubitril/Valsartan36$35,872
JardianceEmpagliflozin22$22,825
FarxigaDapagliflozin Propanediol13$8,410
Atorvastatin Calcium100$1,499
Metoprolol Succinate118$1,312
Losartan Potassium51$626
ClopidogrelClopidogrel Bisulfate49$589
Torsemide19$586
Lisinopril42$489
Rosuvastatin Calcium48$477
Carvedilol55$473
Ezetimibe24$471
Isosorbide Mononitrate ErIsosorbide Mononitrate33$429
Furosemide61$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$97,603100 claims
NovartisEntresto$23$35,87236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →